PRFX (PainReform Ltd) Net Profit

Corporate emblem and logo of painreform.com (PRFX)

Competent management at PainReform Ltd. (PRFX) focuses on preparing drugs for FDA approval. The strategy is based on creating safe alternatives to opioids for postoperative pain management. The implementation of robotic filling lines automates production and documentation. The company's net operating profit reflects the dynamics of these processes, where -0.01 shows the current value of the metric, allowing for an assessment of the issuer's financial stability.

PRFX (PainReform) Company Net Income history from 07/04/2022 to 10/29/2026

Financial and market metric breakdowns for PainReform (PRFX)

- price and consensus price forecast:
Stock Quotes PainReform Corp|PRFX - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization PainReform Corp|PRFX - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share PainReform|PRFX - Company Book Value|Market-to-Book Ratio painreform.com|PRFX - Cumulative Company Assets
- debt and solvency information:
Aggregate Debt to Capital PainReform Ltd.|PRFX - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital PainReform Ltd|PRFX - Company Aggregate Debts|Debts to Book Value PainReform Corp|PRFX - Company Long-Term Debt|Company Short-Term Loans and Borrowings PainReform|Critical Liquidity Ratio painreform.com
- net income and valuation multiples indicators:
PRFX - Net Profit
Fundamental valuation:PRFX PainReform Corp
Flagship merchandise of PainReform Ltd

Investors evaluating the fundamental value of PainReform Ltd. (PRFX) must weigh market capitalization against actual business efficiency. By analyzing the company's net operating income, one can assess the final earnings per share after all expenses, which, for this business model of intellectual analgesic development with outsourced manufacturing, confirms low capital intensity and minimal environmental risks.

Main competitors

Net Income Haleon Corp|KVUE (Kenvue Inc.) - Net Profit|Net Profit veronapharma.com|Net Income MENS (Jyong Biotech)|LGND (Ligand Pharmaceuticals Incorporated) - Final Profit|Company Net Income Amneal Pharmaceuticals Inc AMRX|Perrigo Corp (PRGO) - Company Net Income|ALVO: Net Income|liquidia.com - Profit After Payment of Taxes|GLPG: Net Profit|ANI Pharmaceuticals Inc - Final Profit|MNKD (MannKind Corp.) - Net Profit|Company Net Income Amphastar Corp AMPH|Company Net Income Pacira BioSciences (PCRX)|SPRY (ars-pharma.com) - Final Profit|Company Net Income Theravance Biopharma, Inc. TBPH|AQST (Aquestive Therapeutics Inc) - Profit After Tax|scPharma - Net Profit|TECX - Net Profit|TNXP: Net Profit|SXTC - Net Financial Result|Company Net Income Eupraxia Pharmaceuticals, Inc.|Company Profit BHST (BioHarvest Sciences, Inc.)|Company Net Income Invizyne Technologies, Inc. (EXOZ)|ORMP (oramed.com) - Final Profit|Net Profit ENTX (Entera Bio)|ipatherapeutics.com (HYFT) - Company Net Income|ABVC BioPharma, Inc. - Net Profit|Profit After Tax CPIX|Quantum BioPharma Limited (QNTM) - Company Net Income|Company Net Income FibroGen Corporation (FGEN)|Company Net Income Telomir Pharmaceuticals|RANI: Final Profit|Company Net Income Synergy CHC Corp (SNYR)|Net Income rallybio.com RLYB|Lexaria Bioscience Corp. - Net Income|Final Profit PULM|PTHL - Company Net Income|APM: Company Net Income|LYRA (Lyra Therapeutics) - Net Income|IBO: Profit After Payment of Taxes|TNFA (TNF Pharmaceuticals Inc.) - Net Profit|Company Profit YCBD (cbdMD Corp)|Net Income CYTO (Altamira Therapeutics)|Net Financial Result lipella.com|Company Net Income OptiNose OPTN|PIRS (Pieris Pharmaceuticals Inc) - Profit After Tax|PROC - Company Net Income|Final Profit PTPI (Petros Pharma)|QLI: Net Profit|Profit After Tax SLRN (acelyrin.com)|Net Income TFFP